Efavirenz QD + Zidovudine/Lamivudine BID — Competitive Intelligence Brief

Efavirenz QD + Zidovudine/Lamivudine BID (Efavirenz QD + Zidovudine/Lamivudine BID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NNRTI + 2 NRTIs). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination therapy (NNRTI + 2 NRTIs) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Efavirenz QD + Zidovudine/Lamivudine BID (Efavirenz QD + Zidovudine/Lamivudine BID) — Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal. This combination uses efavirenz (a non-nucleoside reverse transcriptase inhibitor) plus zidovudine and lamivudine (nucleoside reverse transcriptase inhibitors) to suppress HIV replication by blocking reverse transcriptase at multiple points.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Efavirenz QD + Zidovudine/Lamivudine BID TARGET	Efavirenz QD + Zidovudine/Lamivudine BID	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	phase 3	Antiretroviral combination therapy (NNRTI + 2 NRTIs)	HIV reverse transcriptase
Doravirine + tenofovir DF + lamivudine	Doravirine + tenofovir DF + lamivudine	Instituto Mexicano del Seguro Social	marketed	Antiretroviral combination (NNRTI + NRTIs)	HIV reverse transcriptase
Reyataz + Norvir + Truvada	Reyataz + Norvir + Truvada	ViiV Healthcare	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Lamivudine/Zidovudine	Lamivudine/Zidovudine	Bristol-Myers Squibb	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Once-daily ABC+3TC	Once-daily ABC+3TC	Medical Research Council	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
nucleoside reverse transcriptase inhibitors	nucleoside reverse transcriptase inhibitors	French National Agency for Research on AIDS and Viral Hepatitis	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
Zidovudine (drug)	Zidovudine (drug)	Johann Wolfgang Goethe University Hospital	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NNRTI + 2 NRTIs) class)

1. Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · 1 drug in this class
2. Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
3. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
4. ViiV Healthcare · 1 drug in this class